PGC-1α Negatively Regulates Extrasynaptic NMDAR Activity and Excitotoxicity

Clare Puddifoot,1 Marc-Andre Martel,1 Francesc X. Soriano,1 Alberto Camacho,2 Antonio Vidal-Puig,2 David J. A. Wyllie,1 and Giles E. Hardingham1

1Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom, and 2University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge CB2 0QQ, United Kingdom

Underexpression of the transcriptional coactivator PGC-1α is causally linked to certain neurodegenerative disorders, including Huntington’s Disease (HD). HD pathoprogession is also associated with aberrant NMDAR activity, in particular an imbalance between synaptic versus extrasynaptic (NMDAREx) activity. Here we show that PGC-1α controls NMDAREx activity in neurons and that its suppression contributes to mutant Huntingtin (mHtt)-induced increases in NMDAREx activity and vulnerability to excitotoxic insults.

We found that knock-down of endogenous PGC-1α increased NMDAREx activity and vulnerability to excitotoxic insults in rat cortical neurons. In contrast, exogenous expression of PGC-1α resulted in a neuroprotective reduction of NMDAREx currents without affecting synaptic NMDAR activity. Since HD models are associated with mHtt-mediated suppression of PGC-1α expression, as well as increased NMDAREx activity, we investigated whether these two events were linked. Expression of mHtt (148Q) resulted in a selective increase in NMDAREx activity, compared with wild-type Htt (18Q), and increased vulnerability to NMDA excitotoxicity. Importantly, we observed that the effects of mHtt and PGC-1α knockdown on NMDAREx activity and vulnerability to excitotoxicity were nonadditive and occluded each other, consistent with a common mechanism. Moreover, exogenous expression of PGC-1α reversed mHtt-mediated increases in NMDAREx activity and protected neurons against excitotoxic death. The link between mHtt, PGC-1α, and NMDAR activity was also confirmed in rat striatal neurons. Thus, targeting levels of PGC-1α expression may help reduce aberrant NMDAREx activity in disorders where PGC-1α is underexpressed.

Introduction
The transcriptional coactivator peroxisome proliferator-activated receptor-γ coactivator 1a (PGC-1α) controls important physiological processes in many tissues, including glucose metabolism, energy homeostasis, adaptive thermogenesis, and mitochondrial biogenesis (Handschin, 2009). In neurons, PGC-1α regulates mitochondrial density and antioxidant defenses (St-Pierre et al., 2006; Wareski et al., 2009). Moreover, exogenous PGC-1α expression has demonstrable protective/ameliorating effects in models of Huntington’s, Parkinson’s, and Alzheimer’s diseases (HD, PD, and AD, respectively), as well as in ALS and following ischemic/excitotoxic insults (Cui et al., 2006; Luo et al., 2009; Okamoto et al., 2009; Qin et al., 2009; Chen et al., 2010; Shin et al., 2011; Soriano et al., 2011; Zhao et al., 2011; Mudo et al., 2012).

Importantly, underexpression of PGC-1α has been causally linked to disease progression in models of HD and PD, as well as being associated with AD (Cui et al., 2006; Weydt et al., 2006; Okamoto et al., 2009; Qin et al., 2009; Shin et al., 2011). In HD, PGC-1α underexpression is attributable to mutant Huntingtin (mHtt)-mediated transcriptional repression of the PGC-1α promoter (Cui et al., 2006; Weydt et al., 2006). HD is a disorder linked to aberrant NMDAR activity and excitotoxicity, associated with neuronal loss in the cortex and striatum (Fan and Raymond, 2007). Recent studies showed that in an HD mouse model, early elevation of extrasynaptic NMDAR (NMDAREx) activity in the cortex and striatum contributes to phenotype onset (Milnerwood et al., 2010), although the mechanism is unclear. Excessive activation of NMDARExs is known to trigger several prodeath pathways, in contrast to the neuroprotective effects of the transsynaptic activation of synaptic NMDARs (NMDARSyns) (Hardingham and Bading, 2010). In HD, the synaptic/extrasynaptic NMDAR balance plays a key role in regulating mHtt toxicity in cortical and striatal neurons (Okamoto et al., 2009). Furthermore, selective blockade of NMDAREx activity, achieved by low doses of memantine (Xia et al., 2010), ameliorates HD symptoms (Okamoto et al., 2009; Milnerwood et al., 2010).

Here we report that PGC-1α is a negative regulator of NMDAREx activity, offering an explanation for the potent antieexcitotoxic effects of PGC-1α. We also provide evidence that links mHtt’s suppression of PGC-1α expression to the deleterious increase in NMDAREx activity. Together with previous studies (Okamoto et al., 2009; Milnerwood et al., 2010), our study suggests a model whereby mHtt toxicity, NMDAREx activity,
and PGC-1α repression all positively feed back on each other to promote neuronal dysfunction.

Materials and Methods

Neuronal culture, transfection, luciferase assays, immunofluorescence. Cortical and striatal neurons from E21 Sprague Dawley rats of either sex were cultured as described previously (Papadia et al., 2008); experiments were performed at DIV10. Neurons were transfected in trophic transfection medium with plasmids (2 μg/ml total) and/or siRNA (100 nM) using Lipofectamine 2000. Experiments were performed 48 h posttransfection. For luciferase assays, firefly PGC-1α-luc was transfected plus pTK-RL vector (Promega). Immunofluorescence was performed as described previously (Papadia et al., 2008). Antibodies used were DARPP-32 (1:100; Abcam) and PGC-1α (1:50; Millipore).

Plasmids. pcDNA-PGC-1α was a gift from P. Puigserver (Dana Farber Cancer Institute, Boston, MA). pEF-PGC-1α was made by excising the ORF from the pcDNA vector from EcoRI/AgeI sites, blunting and inserting to the EvorV site of pEF/V5-His A vector. Myc-wtHtt-N63-18Q (wtHtt(18Q)) and Myc-mtHtt-N63-148Q (mtHtt(148Q)) were a gift from Chris Ross (John Hopkins Medical School, Baltimore, MD). PGC-1α-luc was a gift from A. Fukamizu (University of Tsukuba, Tsukuba, Japan).

Electrophysiological recording and analysis. NMDA-evoked whole-cell steady-state currents (normalized to cell capacitance) were measured 48 h after transfection, as described previously (Papadia et al., 2008). NMDA (100 μM) was applied for 30 s, repeated twice for each cell. Data were filtered at 1 kHz and digitized at 5 kHz for subsequent off-line analysis. Miniature EPSCs (mEPSCs) recordings were performed and analyzed as described previously (Baxter and Wyllie, 2006). Recordings of NMDAR currents were performed 48 h posttransfection. Neurons were placed in Mg2+-free aCSF (Papadia et al., 2008). After 10 min incubation (sufficient to block NMDA receptors), neurons were washed with Mg2+-free aCSF and treated with 10 μM NMDA exposure (1 h). Cell death assessed at 24 h here and throughout (see Materials and Methods). *p < 0.05; 150 –300 cells analyzed per condition here and in all cell death experiments (n = 3; scale bar, 20 μm). Pre-, Pretreatment; Post-, posttransfection; Si, siRNA. G, Vulnerability of neurons transfected with the indicated plasmids to 20 μM NMDA exposure. *p < 0.05; n = 3.

Figure 1. PGC-1α suppresses extrasynaptic NMDAR activity in cortical neurons. A, Time course of the quantal block of NMDAR currents by MK-801, leaving NMDAR currents unblocked. Neurons were exposed to Mg2+-free aCSF (+ MK-801 + TTX) for the indicated times. NMDA (100 μM)-induced currents were recorded, normalized to capacitance, and expressed relative to total NMDAR currents expressed in cortical neurons. Incubation for 10 min was sufficient for maximal blockade of NMDAR currents; the remaining current represents the extrasynaptic pool (20 cells analyzed). B, Neurons transfected as indicated, plus eGFP marker. NMDAR currents were recorded 48 h posttransfection, normalized to capacitance, and expressed as a percentage relative to control (con) here and throughout. *p < 0.05; n = 5, 7, 7 independent experiments. Each replicate (i.e., n) represents the mean of three to five cells analyzed here and throughout the manuscript. Scale bars, 200 pA, 10 s. C, NMDAR currents measured in β-globin versus PGC-1α-expressing cortical neurons (normalized to β-globin control). *p < 0.05; n = 5, 4. D, Effect of PGC-1α siRNA and PGC-1α expression on total whole-cell NMDAR currents was measured and expressed as a percentage change compared with control. This percentage change was compared with the percentage change observed in NMDAR currents.*p < 0.05; n = 4 –5. E, Total and NMDAR currents were sequentially measured in neurons expressing β-globin (Con) or PGC-1α. NMDAR currents were calculated as total-extrasynaptic currents. *p < 0.05; n = 11 (Con); n = 5 (PGC-1α). Inset shows example traces; scale bar, 500 pA, 100 ms. F, Vulnerability of neurons transfected with the indicated siRNAs to 10 μM NMDA exposure (1 h). Cell death assessed at 24 h here and throughout (see Materials and Methods). *p < 0.05; 150 –300 cells analyzed per condition here and in all cell death experiments (n = 3; scale bar, 30 μm). G, Vulnerability of neurons transfected with the indicated siRNAs to 10 μM NMDA exposure. *p < 0.05; n = 3.
Following the fate of transfected neurons following excitotoxic insult. This procedure was performed as described previously (Papadia et al., 2008; Soriano et al., 2011). Neurons were transfected with the plasmid of interest plus eGFP marker, and pictures taken using a Leica AF6000LX system (DFC350 FX camera) before 10–20 μM NMDA treatment for 1 h, after which 10 μM MK-801 was added. Using cell-finder software, images of the same neurons were taken 24 h post insult. Cell death was determined by counting the number of surviving GF-exprressing cells post insult. Cell death was indentified by the absence of healthy GFP-expressing neurons: in >90% of cases, fluorescent cell debris and fragmented nuclei were observed. For each condition, the fate of 200–300 neurons was monitored over three or four experiments done on independent cultures.

Statistical analysis and controls. Mean ± SEM is shown. All experiments were performed on three to five independent culture batches. In all cases, treatments/interventions were compared with their respective controls within that culture batch (and recorded/measured on the same day), i.e., PGC1α, PGC1α siRNA, and mHtt-expressing/treated neurons were always paired with their respective controls (β-globin, control siRNA, and wild-type Htt (wHtt), respectively) within each culture batch. Statistical testing involved a two-tailed paired or unpaired t test. For studies using multiple testing (e.g., the use of two pairs of siRNA), a one-way ANOVA was used. For studies involving two variables (e.g., siRNAs ± mHtt/wHtt), a two-way ANOVA was used. ANOVA's were followed by Fisher’s least squares difference post hoc test.

Results

PGC-1α controls NMDAR<sup>EX</sup> activity and excitotoxicity

Exogenous PGC-1α expression protects neurons against excitotoxic insults (Luo et al., 2009; Chen et al., 2010; Soriano et al., 2011). Because excessive activation of NMDAR<sup>SYN</sup> is an important mediator of excitotoxicity, we investigated the influence of PGC-1α on NMDAR<sup>SYN</sup> currents. To measure NMDAR<sup>EX</sup> currents, we used the established quantal block technique of blocking NMDAR<sup>SYN</sup>s by incubating neurons with the open-channel blocker MK-801, plus TTX in Mg<sup>2+</sup>-free aCSF (Papadia et al., 2008). Under these conditions, spontaneous presynaptic release of single quanta of glutamate give rise to mEPSCs that activate NMDAR<sup>SYN</sup>s, which are then immediately/irreversibly blocked by MK-801. Subsequent to this open-channel blockade of NMDAR<sup>SYN</sup>s, NMDA-evoked currents are recorded under voltage clamp, and are now only mediated by NMDAR<sup>EX</sup>s that were not activated during the quantal block protocol. Time course experiments revealed that 10 min of MK-801/TTX/zero Mg<sup>2+</sup> treatment is sufficient to achieve blockade of NMDAR<sup>SYN</sup>; longer treatments have no further effect (Fig. 1A).

We studied the effect of knocking down PGC-1α in cortical neurons using two previously validated siRNA sequences (Soriano et al., 2011). We first confirmed that PGC-1α knockdown did not affect the frequency or amplitude of mEPSCs (p = 0.76 or 0.60, respectively; one-way ANOVA, n = 5–6), which (if different) could have affected the rate of MK-801-mediated NMDAR<sup>SYN</sup> blockade. We also confirmed that 10 min of MK-801/TTX/zero Mg<sup>2+</sup> treatment was sufficient for NMDA-induced currents to bottom out in PGC-1α siRNA-transfected neurons (data not shown), reassuring us that the remaining currents were mediated by NMDAR<sup>SYN</sup>s, out of reach of presynaptically released quanta of glutamate. PGC-1α knockdown led to a large increase in NMDAR<sup>EX</sup> currents (>100%; Fig. 1B). Total whole-cell currents were also increased but by a far lower proportion (~40%; Fig. 1D). Assessment of NMDAR currents before and after NMDAR<sup>SYN</sup> blockade revealed that NMDAR<sup>EX</sup> currents represent 34.1 ± 6.5% of whole-cell currents (n = 6). Thus, the PGC-1α siRNA-mediated increase in whole-cell currents is largely attributable to the increase in NMDAR<sup>EX</sup> currents.

In contrast to knock-down, exogenous PGC-1α expression reduced NMDAR<sup>EX</sup> currents (Fig. 1C). Again, the effect was proportionally greater than the effect on total whole-cell currents, indicative of a selective effect on NMDAR<sup>SYN</sup>s (Fig. 1D). To test this selectivity directly, we recorded (in control vs PGC-1α-expressing neurons) total NMDAR currents and NMDAR<sup>EX</sup> currents in the same cell (see Materials and Methods, above), and from this, calculated the NMDAR<sup>SYN</sup> current (i.e., total NMDAR current minus NMDAR<sup>EX</sup> current). We found that, while (as expected) PGC-1α expression reduced NMDAR<sup>EX</sup> currents, it had no effect on NMDAR<sup>SYN</sup> currents (Fig. 1E), confirming the selectivity of PGC-1α’s influence.

Consistent with a role for NMDAR<sup>EX</sup> in excitotoxicity (Hardingham and Bading, 2010), we found that PGC-1α siRNA exacerbated neuronal death in response to a modest (10 μM) dose of NMDA (Fig. 1F), while exogenous expression protected neurons against a higher, more toxic dose (20 μM; Fig. 1G).

mHtt-mediated control of NMDAR<sup>EX</sup> activity via PGC-1α repression

PGC-1α is upregulated in HD patients, HD mouse models, and mHtt-expressing cells due to mHtt-mediated repression of the PGC-1α promoter (Cui et al., 2006; Weydt et al., 2006; Okamoto et al., 2009; Chaturvedi et al., 2010; McConoughy et al., 2010), which we confirmed by studying a PGC-1α reporter and endogenous protein expression (Fig. 2A). Increased cortical/striatal NMDAR<sup>EX</sup> activity is observed in the YAC128 HD mouse, which contributes to phenotype onset (Milnerwood et al., 2010). Given our observations in Figure 1, we investigated the possibility that HD mouse model-associated increases in NMDAR<sup>EX</sup> activity could be at least in part in the suppression of PGC-1α by mHtt.

We first investigated whether acute expression of N-terminal mHtt exon 1 (148Q) had any effect on whole-cell or NMDAR<sup>EX</sup> currents compared with N-terminal wHtt (18Q) control. Our studies focused initially on cortical neurons (Fig. 2) and subsequently striatal neurons (Fig. 3), both of which are affected in HD. As with PGC-1α knockdown experiments, we confirmed that mEPSC frequencies and amplitudes were unaffected (mHtt vs wHtt; p = 0.26 vs 0.31; t test, n = 6). Following the quantal block protocol (described earlier), we verified that 10 min of MK-801/TTX/zero Mg<sup>2+</sup> treatment was sufficient for NMDA-induced currents to bottom-out (data not shown). mHtt expression led to a striking increase in NMDAR<sup>EX</sup> currents compared with wHtt (Fig. 2B), consistent with the YAC128 mouse findings (Milnerwood et al., 2010). Moreover, the mHtt-induced effect on extrasynaptic currents was far more pronounced than its effect on total currents, again indicative of a preferential effect on NMDAR<sup>EX</sup>s over NMDAR<sup>SYN</sup>s (Fig. 2C). In line with previous studies, and consistent with an upregulation of NMDAR<sup>EX</sup> currents, mHtt (but not wHtt) increased neuronal vulnerability to low doses of NMDA (Fig. 2D).

We next investigated the possibility that the effects of mHtt on NMDAR<sup>EX</sup> currents could be due to repression of PGC-1α expression. We tested two predictions of this model: (1) the effects of PGC-1α knockdown and mHtt expression should be nonadditive and occlude each other, and (2) exogenous PGC-1α expression should rescue the effects of mHtt. We studied the effects of combinations of wHtt or mHtt with control or PGC-1α directed siRNA on NMDAR<sup>EX</sup> currents and vulnerability to excitotoxicity. In neurons transfected with PGC-1α siRNA, mHtt had no additional effect on NMDAR<sup>EX</sup> activity compared with wHtt (Fig. 2E, left). Similarly, in neurons expressing mHtt,
PGC-1α siRNA had no additional effect on NMDAR\textsuperscript{E-X} activity compared with control siRNA (Fig. 2 E, left). Moreover the exacerbating effects of PGC-1α siRNA and mHtt on NMDA excitotoxicity were similarly nonadditive and occluded each other (Fig. 2 E, right). These observations support the hypothesis that mHtt triggers increases in NMDAR\textsuperscript{E-X} activity (at least in part) via repression of PGC-1α.

We next performed rescue experiments by driving exogenous PGC-1α expression in mHtt-expressing neurons. This completely reversed the effect of mHtt on NMDAR\textsuperscript{E-X} activity: against a background of PGC-1α overexpression, mHtt had no effect on NMDAR\textsuperscript{E-X} currents (Fig. 2 F, left). Exogenous PGC-1α also protected neurons against mHtt-induced vulnerability to excitotoxicity (Fig. 2 F, right), confirming results from other laboratories. Collectively, these data support a model whereby mHtt suppresses PGC-1α expression, leading to enhanced NMDAR\textsuperscript{E-X} currents, and rescue of mHtt-mediated vulnerability against excitotoxicity can be achieved by restoring PGC-1α expression.

The electrophysiological assessment of synaptic versus extrasynaptic NMDAR currents in striatal cultures is problematic since glutamatergic inputs onto striatal neurons originate from outside the striatum. Our quantal block method could not be used as there would be little spontaneous release of glutamate in such cultures. Nevertheless, we wanted to determine whether mHtt expression and PGC-1α knockdown has nonadditive effects on NMDAR currents and vulnerability to excitotoxicity in striatal cultures (Fig. 3A). As with cortical neurons, both PGC-1α knockdown and mHtt expression increased vulnerability to subtoxic NMDA doses, and the effect of either intervention was just as strong as that of both combined (Fig. 3B). Analysis of NMDAR currents was restricted to total whole-cell currents (i.e., mediated by both NMDAR\textsuperscript{STN} and NMDAR\textsuperscript{E-X}) and revealed that the effects of PGC-1α knockdown and mHtt expression mirrored those observed in cortical neurons (i.e., increasing currents in a nonadditive manner; Fig. 3D). Furthermore, exogenous expression of PGC-1α lowered NMDAR currents, prevented mHtt-mediated increases in NMDAR currents (Fig. 3E), and protected striatal neurons against excitotoxic NMDA exposure (Fig. 3F). These data support the notion that the link between mHtt, PGC-1α, and NMDAR currents applies to both striatal and cortical neurons, the major sites of neurodegeneration in HD.

**Discussion**

This study reveals an unexpected role for PGC-1α in regulating NMDAR\textsuperscript{E-X} activity and, together with recent studies, illuminates
In contrast, NMDAREX activity promotes disaggregation of the chaperonin subunit TCP-1, suppresses mHtt toxicity by the capacity to positively reinforce the other two. For example, something observed in the HD mouse model and rescued by CREB shut-off by dephosphorylation (Hardingham et al., 2002), and the effects of PGC-1α underexpression are likely to be many. For 10 μM NMDA exposure. *p < 0.05; n = 3. Total whole-cell NMDAR currents were measured in striatal neurons transfected with control (con) versus PGC-1α siRNA, plus either wHtt or mHtt, normalized to control/wHtt condition *p < 0.05; n = 6 – 8. D, As in C but in cortical neurons. *p < 0.05; n = 18 – 29. E, Total whole-cell NMDAR currents were measured in striatal neurons transfected with control versus PGC-1α, plus either wHtt or mHtt, normalized to control/wHtt condition. *p < 0.05; n = 5 – 7. F, Vulnerability of neurons transfected as indicated to 20 μM NMDA exposure. *p < 0.05; n = 3. The complex interdependence of PGC-1α, synaptic/extrasynaptic NMDAR activity, and mHtt toxicity.

**Reciprocal links between NMDAR**

*Off activity, mHtt, and PGC-1α*

Recent work from Okamoto and coworkers (2009) showed that the balance between NMDAR**SYN** and NMDAR**EX** activity controls mHtt toxicity. NMDAR**SYN** activity, by inducing expression of the chaperonin subunit TCP-1, suppresses mHtt toxicity by promoting the formation of nontoxic inclusions (Okamoto et al., 2009). In contrast, NMDAR**EX** activity promotes disaggregation of mHtt, enhancing its toxicity associated with Rhes expression, which mediates mHtt sumoylation, disaggregation, and toxicity (Subramaniam et al., 2009). Our study and that of Milnerwood et al. (2010) demonstrates that there is also a reciprocal link: mHtt itself upsets the NMDAR**SYN** balance in favor of NMDAR**EX** activity.

Another known effect of mHtt is suppression of PGC-1α expression, both directly and by increasing NMDAR**EX** activity (Cui et al., 2006; Weydt et al., 2006; Okamoto et al., 2009; Chaturvedi et al., 2010; McConoughey et al., 2010). PGC-1α is a CREB target gene, and enhanced NMDAR**EX** activity is known to trigger CREB shut-off by dephosphorylation (Hardingham et al., 2002), something observed in the HD mouse model and rescued by antagonizing NMDAR**EX**s with low-dose memantine (Milnerwood et al., 2010). Our study shows that the reciprocal relationship also exists: PGC-1α itself controls NMDAR**EX** activity and that mHtt-induced changes in NMDAR**EX** activity are due, at least in part, to its effect on PGC-1α expression.

The consequence of these interdependencies may be a series of positive feedback loops promoting pathoprogession. Any increase in mHtt levels, NMDAR**EX** activity, or PGC-1α promoter repression may become amplified because all three events have the capacity to positively reinforce the other two. For example, aberrant NMDAR**EX** activity is known to suppress CREB-dependent PGC-1α expression and enhance mHtt toxicity. MHtt in turn leads to PGC-1α repression even further, and underexpression of PGC-1α leads to further enhancement of NMDAR**EX** activity, and so on. A prediction of this model would be that therapies aimed at supporting PGC-1α expression (McConoughey et al., 2010) could break the cycle of pathoprogession.

Mechanistically, how PGC-1α lowers NMDAR**EX** expression is unclear. Indeed, mechanisms that control the NMDAR**SYN**:NMDAR**EX** balance in general are poorly understood. One potential influence is GluN2 subunit composition: GluN2A may be enriched at synaptic locations, and GluN2B at extrasynaptic locations, although this is controversial (Hardingham and Bading, 2010). However, we found that the sensitivity of NMDAR whole-cell currents to the GluN2B-specific antagonist was not affected by PGC-1α overexpression (C. Puddifoot, G. Hardingham, unpublished observations), ruling out changes in GluN2 subunit composition as a mechanism. Since PGC-1α can control metabolic pathways, energy homeostasis, mitochondrial biogenesis, and antioxidant defenses (St-Pierre et al., 2006; Handschin, 2009; Wareski et al., 2009), it could be that perturbation to these processes leads to redistribution of NMDARs; for example, through alterations to Ca**2+** levels, energy levels, or redox status. These issues await further investigation.

**PGC-1α repression in other neurodegenerative disorders**

The effects of PGC-1α underexpression are not limited to HD, since PGC-1α repression is observed in AD (Qin et al., 2009) and PD (Shin et al., 2011). In AD, PGC-1α expression was found to be negatively correlated with dementia (Qin et al., 2009). Moreover, overexpression of PGC-1α in Tg2576 AD mouse neurons suppressed amyloidogenic processing of Aβ, promoting α-secretase nonamyloidogenic processing (Qin et al., 2009). Of note, the NMDAR**SYN**:NMDAR**EX** balance also influences Aβ production: NMDAR**SYN** activity promotes α-secretase nonamyloidogenic processing and downregulates APP expression, while NMDAR**EX** activity fails to do this and in fact promotes expression of amyloidogenic isoforms of APP (Hoey et al., 2009; Bordji et al., 2010). Our study suggests the possibility of PGC-1α–NMDAR feedback loops controlling APP processing.

Our study does not question the importance of non-NMDAR-dependent effects of PGC-1α underexpression in neuronal degeneration/dysfunction in neurodegenerative disease. As a regulator of mitochondrial biogenesis and antioxidant defenses, the effects of PGC-1α underexpression are likely to be many. For example, in a recent landmark paper, PGC-1α repression by Parkin-interacting substrate was identified as a causal factor in dopaminergic neuronal loss in models of PD (Shin et al., 2011), a disorder not generally associated with excitotoxicity or aberrant NMDAR**EX** activity. That notwithstanding, the effects of PGC-1α on NMDAR currents, and particularly NMDAR**EX**s, may con-
tribute to the consequences of PGC-1α underexpression in neuro-
ological disorders.

References
Baxter AW, Wylie DJ (2006) Phosphatidylinositol 3 kinase activation and
AMPA receptor subunit trafficking underlie the potentiation of miniature
EPSC amplitudes triggered by the activation of L-type calcium channels.
J Neurosci 26:5466–5469.
Bordj K, Becerril-Ortega J, Nicole O, Buisson A (2010) Activation of extra-
synaptic, but not synaptic, NMDA receptors modifies amyloid precursor
protein expression pattern and increases amyloid-β production. J Neu-
rosci 30:15927–15942.
Chaturvedi RK, Calingasan NY, Yang L, Hennessey T, Johri A, Beal MF
(2010) Impairment of PGC-1alpha expression, neuropathology and he-
aptic seastosis in a transgenic mouse model of Huntington’s disease fol-
Chen SD, Lin TK, Yang DI, Lee SY, Shaw FZ, Liou CW, Chuang YC (2010)
Protective effects of peroxisome proliferator-activated receptors gamma
coaovator-1alpha against neuronal cell death in the hippocampal CA1
Transcriptional repression of PGC-1alpha by mutant huntingtin leads to
lation of PGC-1 promoter activity by protein kinase B and the forkhead
Fan MM, Raymond LA (2007) N-methyl-D-aspartate (NMDA) receptor
function and excitotoxicity in Huntington’s disease. Prog Neurobiol
81:272–293.
Handschin C (2009) The biology of PGC-1alpha and its therapeutic poten-
Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA
receptor signalling: implications for neurodegenerative disorders. Nat
oppose synaptic NMDARs by triggering CREB shut-off and cell death
Hoey SE, Williams RJ, Perkinton MS (2009) Synaptic NMDA receptor ac-
tivation stimulates alpha-secretase amyloid precursor protein processing
PGC-1alpha up-regulation protects the cortical neuron against oxygen-
McConoughey SF, Basso M, Niatsetskaya ZV, Steinman SF, Smirnova NA,
Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B,
Starkov A, Chaturvedi RK, Beal MF, Coppola G, Geschwind DH, Ryu H,
Xia L, Ismaee SE, Pallos J, et al. (2010) Inhibition of transglutaminase 2
mitigates transcriptional dysregulation in models of Huntington disease.
Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd
JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Ray-
mond LA (2010) Early increase in extrasynaptic NMDA receptor signal-
ling and expression contributes to phenotype onset in Huntington’s
Mudo G, Makela J, Liberto VD, Tselykh TV, Olivieri M, Piepptonen P, Er-
iksson O, Malkia A, Bonomo A, Kairisalo M, Aguirre JA, Korthoren L,
Belluardo N, Lindholm D (2012) Transgenic expression and activation
of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model
Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R,
Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G,
Hayden MR, Lipton SA (2009) Balance between synaptic versus extra-
synaptic NMDA receptor activity influences inclusions and neurotoxicity
Papadia S, Soriano FX, Léveillé F, Martel MA, Dakin KA, Hansen HH, Kainid
R, Ghazal P, Horsburgh K, Yankner BA, Wylie DJ, Ikonomidou C, Hard-
ingham GE (2008) Synaptic NMDA receptor activity boosts intrinsic
Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, Pasinetti
GM (2009) PGC-1alpha expression decreases in the Alzheimer disease
Dawson TM (2011) PARIS (ZNF746) repression of PGC-1alpha contrib-
Soriano FX, Léveillé F, Papadia S, Bell KF, Puddifoot C, Hardingham GE
(2011) Neuronal activity controls the antagonistic balance between
PGC-1α and SMRT in regulating antioxidant defences. Antioxid Redox
Signal 14:1425–1436.
pression of reactive oxygen species and neurodegeneration by the PGC-1
specific protein, mediates mutant-huntingtin cytoxicity. Science
324:1327–1330.
Warespi P, Vaarmann A, Chouby V, Sufullina D, Liiv J, Kuun M, Kaasik A
(2009) PGC-1alpha and PGC-1beta regulate mitochondrial density in
Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER,
Gilbert ML, Morton GJ, Bammeler TK, Strand AD, Cui L, Beyer RP, Easley
CN, Smith AC, Strain D, Aponte JA, Lukehart S, Schwartz MW, La Spada AR
(2006) Thermoregulatory and metabolic defects in Huntington’s disease
transgenic mice implicate PGC-1alpha in Huntington’s disease neurode-
blocks extrasynaptic over synaptic NMDA receptor currents in hip-
Zhao W, Varghese M, Yemul S, Cheng A, Marano P, Hassan S, Vem-
pati P, Chen F, Qian X, Pasinetti GM (2011) Peroxisome proliferator
activator receptor gamma coactivator-1alpha (PGC-1alpha) improves
motor performance and survival in a mouse model of amyotrophic lateral